Loading…

Total and differential white blood cell counts, inflammatory markers, adipokines, and incident metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study

The metabolic syndrome is highly prevalent in patients with schizophrenia. We previously found that blood C-reactive protein (CRP), interleukin-6 (IL-6), and leptin levels were predictors of current metabolic syndrome in schizophrenia. In the present study, we investigated whether baseline levels of...

Full description

Saved in:
Bibliographic Details
Published in:Schizophrenia research 2019-07, Vol.209, p.193-197
Main Authors: Kelly, Conor W., McEvoy, Joseph P., Miller, Brian J.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c362t-b050d2977d57d16ab7817af81a15ba57c7b8ed0478cdf5f662df4ada51f4c4793
cites cdi_FETCH-LOGICAL-c362t-b050d2977d57d16ab7817af81a15ba57c7b8ed0478cdf5f662df4ada51f4c4793
container_end_page 197
container_issue
container_start_page 193
container_title Schizophrenia research
container_volume 209
creator Kelly, Conor W.
McEvoy, Joseph P.
Miller, Brian J.
description The metabolic syndrome is highly prevalent in patients with schizophrenia. We previously found that blood C-reactive protein (CRP), interleukin-6 (IL-6), and leptin levels were predictors of current metabolic syndrome in schizophrenia. In the present study, we investigated whether baseline levels of total and differential white blood cell (WBC) counts, inflammatory markers, and adipokines predicted incident metabolic syndrome in schizophrenia. For subjects from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial who did not have metabolic syndrome at baseline (n = 726), WBC counts, inflammatory markers, and adipokines were investigated as predictors of incident metabolic syndrome over 12 months of antipsychotic treatment. Cox proportional hazards regression models, controlling for multiple potential confounding factors, were used to investigate these associations. 39% of subjects (n = 280) had incident metabolic syndrome over 12 months. After controlling for potential confounders, baseline blood IL-6 (HR = 1.12, 95% CI 1.01–1.24, p = 0.031) and leptin (HR = 1.12, 95% CI 1.01–1.24, p = 0.038) were significant predictors of incident metabolic syndrome, and there was a trend-level association with CRP (HR = 1.09, 95% CI 1.00–1.19, p = 0.059). Our findings provide additional evidence that measurement of inflammatory markers and adipokines are germane to the clinical care of patients with schizophrenia. Specifically, these markers may identify—prior to treatment—patients with schizophrenia at heightened risk for incident adverse cardiometabolic effects of antipsychotics. Given the tremendous burden of cardiovascular disease morbidity and mortality in schizophrenia, vigilant screening for and treatment of metabolic risk factors in this patient population are warranted.
doi_str_mv 10.1016/j.schres.2019.04.021
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2232102720</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0920996419301549</els_id><sourcerecordid>2232102720</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-b050d2977d57d16ab7817af81a15ba57c7b8ed0478cdf5f662df4ada51f4c4793</originalsourceid><addsrcrecordid>eNp9kc1u1TAQhSMEoreFN0DISxYk2M6Pkw0SqqAgVWJT1pZjj5W5TeyL7bTKA_JeONzCkpX_vjlzPKco3jBaMcq6D8cq6ilArDhlQ0WbinL2rDiwVtQlb-nwvDjQgdNyGLrmoriM8UgpZS0VL4uLmjHWZ_JQ_LrzSc1EOUMMWgsBXMJ88ThhAjLO3huiYZ6J9qtL8T1BZ2e1LCr5sJFFhXsI-VYZPPl7dLDvsxY6jSZLkQWSGv2MmsTNmeAXyG_kNKkIhBFvSZqA6Bkd6j82Ep7ipiefckUK2UncIXQJwsNuzTsC2aZOmI8QI4lpNdur4oXNKLx-Wq-KH18-311_LW-_33y7_nRb6rrjqRxpSw0fhDCtMKxTo-iZULZnirWjaoUWYw-GNqLXxra267ixjTKqZbbRjRjqq-LdWfcU_M8VYpILxn08yoFfo-S85oxywWlGmzOqg48xgJWngHlem2RU7gHKozwHKPcAJW1kDjCXvX3qsI4LmH9FfxPLwMczAPmfDwghqyA4DQZDHos0Hv_f4TfwpbQy</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2232102720</pqid></control><display><type>article</type><title>Total and differential white blood cell counts, inflammatory markers, adipokines, and incident metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study</title><source>Elsevier</source><creator>Kelly, Conor W. ; McEvoy, Joseph P. ; Miller, Brian J.</creator><creatorcontrib>Kelly, Conor W. ; McEvoy, Joseph P. ; Miller, Brian J.</creatorcontrib><description>The metabolic syndrome is highly prevalent in patients with schizophrenia. We previously found that blood C-reactive protein (CRP), interleukin-6 (IL-6), and leptin levels were predictors of current metabolic syndrome in schizophrenia. In the present study, we investigated whether baseline levels of total and differential white blood cell (WBC) counts, inflammatory markers, and adipokines predicted incident metabolic syndrome in schizophrenia. For subjects from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial who did not have metabolic syndrome at baseline (n = 726), WBC counts, inflammatory markers, and adipokines were investigated as predictors of incident metabolic syndrome over 12 months of antipsychotic treatment. Cox proportional hazards regression models, controlling for multiple potential confounding factors, were used to investigate these associations. 39% of subjects (n = 280) had incident metabolic syndrome over 12 months. After controlling for potential confounders, baseline blood IL-6 (HR = 1.12, 95% CI 1.01–1.24, p = 0.031) and leptin (HR = 1.12, 95% CI 1.01–1.24, p = 0.038) were significant predictors of incident metabolic syndrome, and there was a trend-level association with CRP (HR = 1.09, 95% CI 1.00–1.19, p = 0.059). Our findings provide additional evidence that measurement of inflammatory markers and adipokines are germane to the clinical care of patients with schizophrenia. Specifically, these markers may identify—prior to treatment—patients with schizophrenia at heightened risk for incident adverse cardiometabolic effects of antipsychotics. Given the tremendous burden of cardiovascular disease morbidity and mortality in schizophrenia, vigilant screening for and treatment of metabolic risk factors in this patient population are warranted.</description><identifier>ISSN: 0920-9964</identifier><identifier>EISSN: 1573-2509</identifier><identifier>DOI: 10.1016/j.schres.2019.04.021</identifier><identifier>PMID: 31118157</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>C-reactive protein ; Inflammation ; Interleukin-6 ; Leptin ; Metabolic syndrome ; Schizophrenia</subject><ispartof>Schizophrenia research, 2019-07, Vol.209, p.193-197</ispartof><rights>2019 Elsevier B.V.</rights><rights>Copyright © 2019 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-b050d2977d57d16ab7817af81a15ba57c7b8ed0478cdf5f662df4ada51f4c4793</citedby><cites>FETCH-LOGICAL-c362t-b050d2977d57d16ab7817af81a15ba57c7b8ed0478cdf5f662df4ada51f4c4793</cites><orcidid>0000-0001-5056-4515</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31118157$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kelly, Conor W.</creatorcontrib><creatorcontrib>McEvoy, Joseph P.</creatorcontrib><creatorcontrib>Miller, Brian J.</creatorcontrib><title>Total and differential white blood cell counts, inflammatory markers, adipokines, and incident metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study</title><title>Schizophrenia research</title><addtitle>Schizophr Res</addtitle><description>The metabolic syndrome is highly prevalent in patients with schizophrenia. We previously found that blood C-reactive protein (CRP), interleukin-6 (IL-6), and leptin levels were predictors of current metabolic syndrome in schizophrenia. In the present study, we investigated whether baseline levels of total and differential white blood cell (WBC) counts, inflammatory markers, and adipokines predicted incident metabolic syndrome in schizophrenia. For subjects from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial who did not have metabolic syndrome at baseline (n = 726), WBC counts, inflammatory markers, and adipokines were investigated as predictors of incident metabolic syndrome over 12 months of antipsychotic treatment. Cox proportional hazards regression models, controlling for multiple potential confounding factors, were used to investigate these associations. 39% of subjects (n = 280) had incident metabolic syndrome over 12 months. After controlling for potential confounders, baseline blood IL-6 (HR = 1.12, 95% CI 1.01–1.24, p = 0.031) and leptin (HR = 1.12, 95% CI 1.01–1.24, p = 0.038) were significant predictors of incident metabolic syndrome, and there was a trend-level association with CRP (HR = 1.09, 95% CI 1.00–1.19, p = 0.059). Our findings provide additional evidence that measurement of inflammatory markers and adipokines are germane to the clinical care of patients with schizophrenia. Specifically, these markers may identify—prior to treatment—patients with schizophrenia at heightened risk for incident adverse cardiometabolic effects of antipsychotics. Given the tremendous burden of cardiovascular disease morbidity and mortality in schizophrenia, vigilant screening for and treatment of metabolic risk factors in this patient population are warranted.</description><subject>C-reactive protein</subject><subject>Inflammation</subject><subject>Interleukin-6</subject><subject>Leptin</subject><subject>Metabolic syndrome</subject><subject>Schizophrenia</subject><issn>0920-9964</issn><issn>1573-2509</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1TAQhSMEoreFN0DISxYk2M6Pkw0SqqAgVWJT1pZjj5W5TeyL7bTKA_JeONzCkpX_vjlzPKco3jBaMcq6D8cq6ilArDhlQ0WbinL2rDiwVtQlb-nwvDjQgdNyGLrmoriM8UgpZS0VL4uLmjHWZ_JQ_LrzSc1EOUMMWgsBXMJ88ThhAjLO3huiYZ6J9qtL8T1BZ2e1LCr5sJFFhXsI-VYZPPl7dLDvsxY6jSZLkQWSGv2MmsTNmeAXyG_kNKkIhBFvSZqA6Bkd6j82Ep7ipiefckUK2UncIXQJwsNuzTsC2aZOmI8QI4lpNdur4oXNKLx-Wq-KH18-311_LW-_33y7_nRb6rrjqRxpSw0fhDCtMKxTo-iZULZnirWjaoUWYw-GNqLXxra267ixjTKqZbbRjRjqq-LdWfcU_M8VYpILxn08yoFfo-S85oxywWlGmzOqg48xgJWngHlem2RU7gHKozwHKPcAJW1kDjCXvX3qsI4LmH9FfxPLwMczAPmfDwghqyA4DQZDHos0Hv_f4TfwpbQy</recordid><startdate>201907</startdate><enddate>201907</enddate><creator>Kelly, Conor W.</creator><creator>McEvoy, Joseph P.</creator><creator>Miller, Brian J.</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5056-4515</orcidid></search><sort><creationdate>201907</creationdate><title>Total and differential white blood cell counts, inflammatory markers, adipokines, and incident metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study</title><author>Kelly, Conor W. ; McEvoy, Joseph P. ; Miller, Brian J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-b050d2977d57d16ab7817af81a15ba57c7b8ed0478cdf5f662df4ada51f4c4793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>C-reactive protein</topic><topic>Inflammation</topic><topic>Interleukin-6</topic><topic>Leptin</topic><topic>Metabolic syndrome</topic><topic>Schizophrenia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kelly, Conor W.</creatorcontrib><creatorcontrib>McEvoy, Joseph P.</creatorcontrib><creatorcontrib>Miller, Brian J.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Schizophrenia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kelly, Conor W.</au><au>McEvoy, Joseph P.</au><au>Miller, Brian J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Total and differential white blood cell counts, inflammatory markers, adipokines, and incident metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study</atitle><jtitle>Schizophrenia research</jtitle><addtitle>Schizophr Res</addtitle><date>2019-07</date><risdate>2019</risdate><volume>209</volume><spage>193</spage><epage>197</epage><pages>193-197</pages><issn>0920-9964</issn><eissn>1573-2509</eissn><abstract>The metabolic syndrome is highly prevalent in patients with schizophrenia. We previously found that blood C-reactive protein (CRP), interleukin-6 (IL-6), and leptin levels were predictors of current metabolic syndrome in schizophrenia. In the present study, we investigated whether baseline levels of total and differential white blood cell (WBC) counts, inflammatory markers, and adipokines predicted incident metabolic syndrome in schizophrenia. For subjects from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial who did not have metabolic syndrome at baseline (n = 726), WBC counts, inflammatory markers, and adipokines were investigated as predictors of incident metabolic syndrome over 12 months of antipsychotic treatment. Cox proportional hazards regression models, controlling for multiple potential confounding factors, were used to investigate these associations. 39% of subjects (n = 280) had incident metabolic syndrome over 12 months. After controlling for potential confounders, baseline blood IL-6 (HR = 1.12, 95% CI 1.01–1.24, p = 0.031) and leptin (HR = 1.12, 95% CI 1.01–1.24, p = 0.038) were significant predictors of incident metabolic syndrome, and there was a trend-level association with CRP (HR = 1.09, 95% CI 1.00–1.19, p = 0.059). Our findings provide additional evidence that measurement of inflammatory markers and adipokines are germane to the clinical care of patients with schizophrenia. Specifically, these markers may identify—prior to treatment—patients with schizophrenia at heightened risk for incident adverse cardiometabolic effects of antipsychotics. Given the tremendous burden of cardiovascular disease morbidity and mortality in schizophrenia, vigilant screening for and treatment of metabolic risk factors in this patient population are warranted.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>31118157</pmid><doi>10.1016/j.schres.2019.04.021</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0001-5056-4515</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0920-9964
ispartof Schizophrenia research, 2019-07, Vol.209, p.193-197
issn 0920-9964
1573-2509
language eng
recordid cdi_proquest_miscellaneous_2232102720
source Elsevier
subjects C-reactive protein
Inflammation
Interleukin-6
Leptin
Metabolic syndrome
Schizophrenia
title Total and differential white blood cell counts, inflammatory markers, adipokines, and incident metabolic syndrome in phase 1 of the clinical antipsychotic trials of intervention effectiveness study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T17%3A58%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Total%20and%20differential%20white%20blood%20cell%20counts,%20inflammatory%20markers,%20adipokines,%20and%20incident%20metabolic%20syndrome%20in%20phase%201%20of%20the%20clinical%20antipsychotic%20trials%20of%20intervention%20effectiveness%20study&rft.jtitle=Schizophrenia%20research&rft.au=Kelly,%20Conor%20W.&rft.date=2019-07&rft.volume=209&rft.spage=193&rft.epage=197&rft.pages=193-197&rft.issn=0920-9964&rft.eissn=1573-2509&rft_id=info:doi/10.1016/j.schres.2019.04.021&rft_dat=%3Cproquest_cross%3E2232102720%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c362t-b050d2977d57d16ab7817af81a15ba57c7b8ed0478cdf5f662df4ada51f4c4793%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2232102720&rft_id=info:pmid/31118157&rfr_iscdi=true